Press Releases

                                                                                                          Lysaker, 4 June 2024

Privately taxed investors in funds managed by Storebrand Asset Management AS are subject to minimum income tax (minimumsudlodning) for 2024.

Investors who owned units in the equity funds below on 17 April 2024 (value date 19 April), will be... (continue reading...)

STOCKHOLM, June 4, 2024 /PRNewswire/ -- CheckProof, a Swedish SaaS company, is thrilled to announce a significant investment and long-term partnership with Viking Venture, the leading Nordic B2B software investor. 

CheckProof provides a user-friendly, all-in-one platform for the construction materials industry. The platform digitizes Maintenance & HSEQ Management with tasks including quality and maintenance routines, defects, deviation, and incident... (continue reading...)

OSLO, Norway, June 4, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced activities to support a new initiative enabling U.S. Hospitals and Clinics to offer blue light cystoscopy (BLC®) using a mobile capital equipment model. The initiative is aligned with a recently executed agreement between Karl Storz and ForTec Medical, aimed at providing on-demand Saphira™ BLC equipment to hospitals in the U.S.... (continue reading...)

PARIS--(BUSINESS WIRE)-- Regulatory News:

In line with its strategy to grow its liquefied natural gas (LNG) business, TotalEnergies (Paris: TTE) (LSE: TTE) (NYSE: TTE) announces the signing of two new LNG medium- and long-term contracts in Asia:

• a sales and purchase agreement (SPA) with Indian Oil Corporation (IOCL) for the delivery to India of up to 800,000 tons per year of LNG for ten years from 2026; and

• an agreement (HoA) with Korea South-East Power for... (continue reading...)

• ADESOS Phase 2b study evaluating orismilast as an oral treatment in 233 patients with moderate-to-severe atopic dermatitis (AD) has successfully completed
• Results from the ADESOS study have been selected for an oral presentation at the late breaking research sessions at the RAVE Conference 2024
• Orismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2 study in hidradenitis... (continue reading...)